Anticoagulant thrombins

Trends in Cardiovascular Medicine

Volumn 8, Issue 8, 1998, Pages 340-350

  Di Cera, Enrico ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR; FIBRINOPEPTIDE A; FIBRINOPEPTIDE B; PROTEIN C; SODIUM ION; THROMBIN; THROMBOMODULIN;

ALLOSTERISM; ANTICOAGULATION; BINDING SITE; BLOOD CLOTTING; ENZYME BINDING; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0031672696     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(98)00030-9     Document Type: Article

References (47)

1. Banfield DK, MacGillivray RTA: 1992. Partial characterization of vertebrate prothrombin cDNAs: amplification and sequence analysis of the B chain of thrombin from nine different species. Proc Natl Acad Sci USA 89:2779-2783.
2. Berg DT, Wiley MR, Grinnell BW: 1996. Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator. Science 273:1389-1391.
3. Bode W, Turk D, Karshikov A: 1992. The refined 1.9-Å X-ray crystal structure of D-Phe-Pro-Arg-chloromethylketone-inhibited human α-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1:426-471.
4. Brady SF, Stauffer KJ, Lumma WC, et al.: 1998. Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support. J Med Chem 41: 401-406.
5. Brezniak DV, Brower MS, Witting JI, Walz DA, Fenton JW: 1990. Human α to ζ-thrombin cleavage occurs with neutrophil cathepsin G or chymotrypsin while fibrinogen clotting activity is retained. Biochemistry 29:536-542.
6. +-induced allosteric regulation of catalytic activity in serine proteases. Proc Natl Acad Sci USA 93:10,653-10,656.
7. Dang QD, Vindigni A, Di Cera E: 1995. An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. Proc Natl Acad Sci USA 92:5977-5981.
8. Dang QD, Guinto ER, Di Cera E: 1997a. Rational engineering of activity and specificity in a serine protease. Nat Biotechnol 15:146-149.
9. Dang QD, Sabetta M, Di Cera E: 1997b. Selective loss of fibrinogen clotting in a loop-less thrombin. J Biol Chem 272:19,649-19,651.
10. Davie EW, Fujikawa K, Kisiel W: 1991. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30: 10,363-10,370.
11. Di Cera E, Dang QD, Ayala YM: 1997. Molecular mechanisms of thrombin function. Cell Mol Life Sci 15:701-730.
12. + binding site of thrombin. J Biol Chem 270:22,089-22,092.
13. Dickinson CD, Kelly CR, Ruf W: 1996. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. Proc Natl Acad Sci USA 93:14,379-14,384.
14. Feng DM, Gardell SJ, Lewis SD, et al.: 1997. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the Pl position. J Med Chem 40:3726-3733.
15. Fenton JW: 1988. Thrombin specificity. Ann NY Acad Sci 370:468-495.
16. Gan ZR, Li Y, Connolly TM, Sardana MK, et al.: 1993. Importance of the Arg-Gly-Asp triplet in human thrombin for maintenance of structure and function. Arch Biochem Biophys 301:228-236.
17. Gibbs CS, Coutre SE, Tsiang M, et al.: 1995. Conversion of thrombin into an anticoagulant by protein engineering. Nature 378: 413-416.
18. Grinnell BW: 1997. Tipping the balance of blood coagulation. Nat Biotechnol 15:124-125.
19. Guinto ER, Di Cera E: 1997. Critical role of W60d in thrombin allostery. Biophys Chem 64:103-109.
20. Hall SW, Gibbs CS, Leung LLK: 1997. Strategies for development of novel antithrombotics: modulating thrombin's procoagulant and anticoagulant properties. Cell Mol Life Sci 53:731-736.
21. 517→Gln, identified in an individual heterozygous for dysprothrombinemia. Blood 91:2026-2031.
22. Hofsteenge J, Braun PJ, Stone SR: 1988. Enzymatic properties of proteolytic derivatives of human α-thrombin. Biochemistry 27:2144-2151.
23. Kalafatis M, Egan JO, van't Veer C, Cawthern KM, Mann KG: 1997. The regulation of clotting factors. Crit Rev Eukaryot Gene Expr 7:241-280.
24. + binding. Proteins Struct Funct Genet 52:32-43.
25. Kurz KD, Smith T, Wilson A, Gerlitz B, Richardson MA, Grinnell BW: 1997. Antithrombotic efficacy in the Guinea pig of a derivative of human protein C with enhanced activation by thrombin. Blood 89:534-540.
26. Lai MT, Di Cera E, Shafer JA: 1997. Kinetic pathway for the slow to fast transition of thrombin. Evidence of linked ligand binding at structurally distinct domains. J Biol Chem 272:30,275-30,282.
27. Lesk AM, Fordham WD: 1996. Conservation and variability in the structures of serine proteinases of the chymotrypsin family. J Mol Biol 258:501-537.
28. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S: 1990. Surface dependent reactions of the vitamin K-dependent enzyme complexes. Blood 76:1-16.
29. Martin PD, Robertson W, Turk D, Huber R, Bode W, Edwards BFP: 1992. The structure of residues 7-16 of the Aα chain of human fibrinogen bound to bovine thrombin at 2.3 Å resolution J Biol Chem 267: 7911-7920.
30. Mathews II, Padmanabhan KP, Tulinsky A, Sadler JE: 1994a. Structure of a nonadecapeptide of the fifth EGF domain of thrombomodulin complexed with thrombin. Biochemistry 33:13,547-13,552.
31. Mathews II, Padmanabhan KP, Ganesh V, et al.: 1994b. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry 33: 3266-3279.
32. Miyata T, Aruga R, Umeyama H, Bezeaud A, Guillin MC, Iwanaga S: 1992. Prothrombin Salakta: substitution of glutamic acid-466 by alanine reduces the fibrinogen clotting activity and the esterase activity. Biochemistry 31:7457-7462.
33. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG: 1996. Blood clotting in minimally altered whole blood. Blood 88:3432-3445.
34. Raskob GE: 1995. Low molecular weight heparin, heparin and warfarin. Curr Opin Hematol 2:372-379.
35. Rawlings RD, Barrett AJ: 1993. Evolutionary families of peptidases. Biochem J 290:205-218.
36. Rydel TJ, Tulinsky A, Bode W, Huber R: 1991. Refined structure of the hirudin-thrombin complex. J Mol Biol 221:583-601.
37. Sadler JE: 1997. Thrombomodulin structure and function. Thromb Haemost 78:392-395.
38. Shainoff JR, Smejkal GB, DiBello PM, et al.: 1996. Isolation and characterization of the fibrin intermediate arising from cleavage of one fibrinopeptide A from fibrinogen. J Biol Chem 271:24,129-24,137.
39. Stubbs M, Oschkinat H, Mayr I, et al.: 1992. The interaction of thrombin with fibrinogen: a structural basis for its specificity. Eur J Biochem 206:187-195.
40. Tsiang M, Jain AK, Dunn KE, Rojas ME, Leung LLK, Gibbs CS: 1995. Functional mapping of the surface residues of human thrombin. J Biol Chem 270:16,854-16,863.
41. Tsiang M, Paborsky LR, Li WX, et al.: 1996. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry 35:16,449-16,457.
42. Vindigni A, Dang QD, Di Cera E: 1997. Site-specific dissection of substrate recognition by thrombin. Nat Biotechnol 15:891-895.
43. Vu TKH, Wheaton VI, Hung DT, Charo I, Coughlin SR: 1991. Domains defining thrombin receptor interactions. Nature 353: 674-677.
44. +-activated enzyme. Biochemistry 31: 11,721-11,730.
45. Wu Q, Sheehan JP, Tsiang M, Lentz SR, Birktoft JJ, Sadler JE: 1991. Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin. Proc Natl Acad Sci USA 88:6775-6779.
46. Yan SB, Grinnell BW: 1994. Recombinant human protein C, protein S and thrombomodulin as antithrombotics. Perspect Drug Disc Des 1:503-520.
47. + binding site of thrombin. Biophys Chem 63:185-200.